

Table 2d. Antibody Performance, Weeks 3 to 5 – Total Antibodies

Total	Week 3			Week 4			Week 5		
Sensitivity	0.98 (95% CI: 0.89 to 1.00)			0.95 (95% CI: 0.84 to 0.99)			0.95 (95% CI: 0.90 to 0.98)		
Specificity	1.00 (95% CI: 0.99 to 1.00)								
Outcome	Effect per 1,000 patients tested								
	Pre-test Probability								
	1% ^a	10% ^b	40% ^c	1% ^a	10% ^b	40% ^c	1% ^a	10% ^b	40% ^c
True positives (patients with COVID-19)	10 (9 to 10)	98 (89 to 100)	392 (356 to 400)	5 (4 to 5)	95 (84 to 99)	380 (336 to 396)	5 (5 to 5)	95 (90 to 98)	380 (360 to 392)
False negatives (patients incorrectly classified as not having COVID-19)	0 (0 to 1)	2 (0 to 11)	8 (0 to 44)	0 (0 to 1)	5 (1 to 16)	20 (4 to 64)	0 (0 to 0)	5 (2 to 10)	20 (8 to 40)
Quality of the evidence	6 studies, 472 patients ⊕⊕⊕○ MODERATE ^d			2 studies, 289 patients ⊕⊕○○ LOW ^{d,e}			1 study, 121 patients ⊕⊕○○ LOW ^{d,e}		
	pre-test probability of 1% ^a			pre-test probability of 10% ^b			pre-test probability of 40% ^c		
True negatives (patients without COVID-19)	990 (980 to 990)			900 (891 to 900)			600 (594 to 600)		
False positives (patients incorrectly classified as having COVID-19)	0 (0 to 10)			0 (0 to 9)			0 (0 to 6)		
Quality of Evidence	8 studies, 4521 patients ⊕⊕⊕○ MODERATE ^d								
<p>a. Typically seen in general population in areas that are not hotspots</p> <p>b. Typically seen in general population in high risk populations</p> <p>c. Typically seen in general population in exposed and nursing homes</p> <p>d. The case-control design leads to a serious risk of bias</p> <p>e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C3: 0.78-1.00, C4: 0.88-0.94, C5: 0.95</p>									